Fidaxomicin: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
* Antibiotics indicated for [[Clostridioides difficile]] infection |
* Antibiotics indicated for [[Clostridioides difficile]] infection |
||
* Standard dose is 200 mg p.o. twice daily for 10 days |
* Standard dose is 200 mg p.o. twice daily for 10 days |
||
* Pulse-tapered regimen is 200 mg twice daily for days 1 to 5, followed by 200 mg every other days 7 to 25[[CiteRef::guery2018ex]][[CiteRef::skinner2021a]] |
* Pulse-tapered regimen is 200 mg twice daily for days 1 to 5, followed by 200 mg every other days 7 to 25[[CiteRef::guery2018ex]], or 200 mg twice daily for 10 days then daily for 7 days then every other day for 13 doses[[CiteRef::skinner2021a]] |
||
* In Ontario, EAP criteria for approval through the telephone request service includes: third or subsequent episode treated with vancomycin within 6 months; treatment failure despite at least 7 days of vancomycin; allergy to oral vancomycin; severe adverse reaction or intolerance to oral vancomycin |
* In Ontario, EAP criteria for approval through the telephone request service includes: third or subsequent episode treated with vancomycin within 6 months; treatment failure despite at least 7 days of vancomycin; allergy to oral vancomycin; severe adverse reaction or intolerance to oral vancomycin |
||
Latest revision as of 14:57, 8 April 2026
- Antibiotics indicated for Clostridioides difficile infection
- Standard dose is 200 mg p.o. twice daily for 10 days
- Pulse-tapered regimen is 200 mg twice daily for days 1 to 5, followed by 200 mg every other days 7 to 251, or 200 mg twice daily for 10 days then daily for 7 days then every other day for 13 doses2
- In Ontario, EAP criteria for approval through the telephone request service includes: third or subsequent episode treated with vancomycin within 6 months; treatment failure despite at least 7 days of vancomycin; allergy to oral vancomycin; severe adverse reaction or intolerance to oral vancomycin
References
- ^ Benoit Guery, Francesco Menichetti, Veli-Jukka Anttila, Nicholas Adomakoh, Jose Maria Aguado, Karen Bisnauthsing, Areti Georgopali, Simon D Goldenberg, Andreas Karas, Gbenga Kazeem, Chris Longshaw, Jose Alejandro Palacios-Fabrega, Oliver A Cornely, Maria J G T Vehreschild. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. The Lancet Infectious Diseases. 2018;18(3):296-307. doi:10.1016/s1473-3099(17)30751-x.
- ^ Andrew M Skinner, Xing Tan, Benjamin D Sirbu, Larry H Danziger, Dale N Gerding, Stuart Johnson. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences. Clinical Infectious Diseases. 2021;73(6):1107-1109. doi:10.1093/cid/ciab233.
